Healthcare technology company
Appears in 6 stories · Last updated Oct 25, 2026
Competitor in remote heart failure monitoring
Heart failure patients with Abbott's implanted pressure sensor will be able to see their own readings on a smartphone. The FDA approved the update on Oct. 5, 2026, and Abbott says the CardioGuide HF App will reach U.S. patients later in 2026.
Updated Oct 25
Manufacturer of the VenaSeal closure system used in the Spectrum program
Four late-breaking trials at The VEINS 2026 conference in Las Vegas reported results for catheter-based venous disease treatments. They covered iliac vein stenting for post-thrombotic syndrome, single-session mechanical thrombectomy for deep vein thrombosis, cyanoacrylate closure for venous leg ulcers, and an interim look at a pulmonary embolism device.
Updated Oct 22
As of September 2026: Developer of Hugo RAS; maker of LigaSure vessel sealing
The Food and Drug Administration cleared Medtronic's LigaSure vessel-sealing jaw for use on its Hugo surgical robot on September 16. LigaSure has sealed vessels in 45 million procedures over two decades; this is its first robotic version, cutting and closing vessels up to 7 millimeters in about two seconds each.
Updated Sep 18
As of September 2026: Recalling Bravo CF capsule delivery devices; issuing replacements
The Bravo CF device attaches a pH-monitoring capsule to the esophagus so doctors can diagnose acid reflux. In 761 reported instances since early 2025, the capsule failed to attach or detach as intended, and 184 of those involved serious injuries.
Updated Sep 4
As of May 2026: Manufacturer of the OmniaSecure lead; market leader in cardiac rhythm management
For decades, defibrillators have saved lives by shocking dangerously fast rhythms back to normal, but the leads also pace the heart unnaturally and can cause damage over time. Medtronic's OmniaSecure lead is the first defibrillation lead that can pace through the heart's own electrical wiring, closely mimicking natural heartbeats. It has been cleared by the FDA for placement in the left bundle branch area.
Updated May 30
As of May 2026: Developer and manufacturer of INFUSE bone graft
Medtronic's INFUSE bone graft has spent 24 years navigating FDA approval, off-label controversy, and lawsuits. The FDA just approved INFUSE for transforaminal lumbar interbody fusion (TLIF) procedures—the only growth factor bone graft approved for two-level spinal constructs and the only one cleared for anterior, oblique, and transforaminal approaches.
Updated May 29
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
